NEMUS Bioscience, Inc. a Nevada corporation (the “Company”), announced
that its common stock is now eligible for quotation on the OTC Bulletin
Board under the ticker symbol (NMUS). NEMUS completed a reverse merger
with Load Guard Logistics, Inc. (“LGL”), a Nevada corporation, on
October 31, 2014. During the transition period, the Company’s common
stock had been quoted under the symbol LGLRD.
In connection with the merger, LGL issued a total of 12,880,000 shares
of common stock in exchange for all of the outstanding shares of common
stock of NEMUS and LGL thereafter repurchased and retired 5,431,460
shares of common stock from the company’s former officers and directors
in exchange for all of the issued and outstanding shares of LGT, Inc.,
LGL’s historical operating subsidiary. Following the completion of the
merger and the retirement of the shares of LGL, the Company has a total
of 16,000,000 shares of common stock issued and outstanding. As a result
of the transaction contemplated by the Merger Agreement, the Company’s
sole business operations are that of NEMUS.
NEMUS is a biopharmaceutical company focused on the discovery,
development and commercialization of cannabis-based therapeutics. The
Company is currently the sole partner of the University of Mississippi
for the development and commercialization of drugs derived from cannabis
extracts, or cannabinoids, and the realization of this partnership will
depend on the successful navigation of the complex regulatory framework
for the cultivation and handling of cannabis in the United States. The
University of Mississippi has held the only contract to cultivate
cannabis for research purposes on behalf of the Federal Government since
1968.
About NEMUS Bioscience, Inc.
The Company is a biopharmaceutical company, headquartered in Costa Mesa,
California, focused on the discovery, development, and commercialization
of cannabis-based therapeutics for global markets with significant unmet
medical needs. Utilizing certain proprietary technology licensed from
the University of Mississippi, NEMUS is working to develop novel ways to
deliver cannabis-based drugs for specific indications, with the aim of
optimizing the clinical effects of such drugs, while limiting the
potential adverse events. NEMUS’s strategy is not limited to the sole
use of either natural or synthetic inputs.
The Company is led by a highly qualified team of executives with decades
of biopharmaceutical experience and significant background in
early-stage drug development.
For more information, visit www.nemusbioscience.com.
Forward Looking Statements
Statements in this document that are not descriptions of historical
facts are forward-looking statements that are based on management’s
current expectations and assumptions and are subject to risks and
uncertainties. If such risks or uncertainties materialize or such
assumptions prove incorrect, our business, operating results, financial
condition and stock price could be materially negatively affected. In
some cases, forward-looking statements can be identified by terminology
including “goal,” “focus,” “aims,” “believes,” “can,” “challenge,”
”predictable,” “will,” or the negative of these terms or other
comparable terminology. We operate in a rapidly-changing environment and
new risks emerge from time to time. As a result, it is not possible for
our management to predict all risks, nor can we assess the impact of all
factors on our business or the extent to which any factor, or
combination of factors, may cause actual results to differ materially
from those contained in any forward-looking statements the Company may
make.
Copyright Business Wire 2014